Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements,
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback